International Journal of Medical Science and Health Research

Vol.9, No.06; 2025

ISSN: 2581-3366

The Vagus Nerve: A Dual-function Modulator of Inflammation in the Gut-brain Axis and an Emerging Therapeutic Target

Mehmet ÜNAL
Kocaeli-Turkey
Correspondence: Mehmet ÜNAL, Kocaeli-Turkey. Tel: 05442536432

doi: 10.51505/ijmshr.2025.9607 URL: http://dx.doi.org/10.51505/ijmshr.2025.9607

Received: Nov 12, 2025 Accepted: Nov 20, 2025 Online Published: Nov 29, 2025

Abstract

The Gut-Brain Axis (GBA) is a complex, bidirectional communication network where persistent low-grade inflammation is central to the pathogenesis of numerous disorders, including Inflammatory Bowel Disease (IBD) and mood disorders. The **Vagus Nerve (CN X)** stands as the principal neural interface within this axis, dynamically regulating the host's inflammatory set-point. This review elucidates the Vagus Nerve's **dual function** as both an acute sensor of microbial and inflammatory signals (via approximately 80% afferent fibers) and a potent downregulator of the immune response (via efferent fibers). The efferent pathway mediates the **Cholinergic Anti-Inflammatory Pathway (CAP)**, an essential neurophysiological reflex. Upon activation, the Vagus Nerve releases **Acetylcholine** (ACh), which binds to the **alpha 7 nicotinic Acetylcholine Receptor** (α7nAChR) on immune cells (macrophages). This interaction initiates an inhibitory cascade, suppressing the nuclear translocation of NF-kappa-beta and thereby inhibiting the release of key pro-inflammatory cytokines such as Tumor Necrosis Factor alpha (TNF-alpha) and Interleukin-6 (IL-6). Dysfunction in vagal tone is strongly correlated with increased disease activity and inflammation in IBD, chronic pain, and neurodegenerative disorders. Given its vital role, the Vagus Nerve has emerged as a promising therapeutic target. Strategies like **Invasive and Non-Invasive Vagus Nerve Stimulation (VNS)**, particularly Transcutaneous Auricular VNS (tVNS), are actively being investigated for their potential to restore parasympathetic balance and leverage the CAP to mitigate systemic inflammation. Furthermore, behavioral techniques and microbiota-modulating interventions that boost SCFA production act as indirect vagal enhancers. The Vagus Nerve thus represents a critical frontier in bioelectronic medicine for developing non-pharmacological, targeted treatments for inflammation-driven pathologies.

Keywords: Gut-Brain Axis; Vagus Nerve; Inflammation; Cholinergic Anti-Inflammatory Pathway (CAP); Vagus Nerve Stimulation (VNS); alpha 7 Nicotinic Acetylcholine Receptor; IBD (Inflammatory Bowel Disease); Microbiota; Heart Rate Variability (HRV); Bioelectronic Medicine; Neuroimmunology.

Vol.9, No.06; 2025

ISSN: 2581-3366

1. Introduction: The Vagus Nerve at the Neuro-Immune Crossroads

The **Gut-Brain Axis (GBA)**, a complex, integrated system, coordinates communication between the central nervous system (CNS), the enteric nervous system (ENS), the neuroendocrine system, and the peripheral immune system, all modulated intrinsically by the gut microbiota (Cryan & Dinan, 2012; Bonaz et al., 2018). This intricate communication is fundamental to maintaining physiological homeostasis, including coordination of energy balance, mood regulation, and effective immune defense. A central finding in modern pathophysiology is the critical involvement of chronic, low-grade systemic inflammation in driving numerous chronic conditions, ranging from gastrointestinal disorders (e.g., IBD, IBS) to major neuropsychiatric and neurodegenerative diseases (Pellissier et al., 2014; Porges, 2007; Tsilimigras et al., 2023).

The **Vagus Nerve (CN X)**, which is the tenth cranial nerve, is the principal neural conduit linking the brainstem to the abdominal and thoracic viscera. With approximately 80% afferent fibers, its anatomy dictates its primary role as a visceral sensory system, constantly feeding information to the brain (Tracey, 2007; Bonaz et al., 2017). Uniquely, the Vagus Nerve is positioned to not only sense the peripheral inflammatory status but also to actively modulate it via a rapid, neuro-effector pathway—the Cholinergic Anti-Inflammatory Pathway (CAP). This comprehensive review aims to establish the Vagus Nerve's critical role in the GBA, elaborate on the precise cellular and molecular mechanics of the CAP, and evaluate the emerging therapeutic strategies that leverage vagal signaling to combat chronic inflammation.

2. Vagal Communication: Bidirectional Signaling and Neuroanatomy

The Vagus Nerve's profound influence stems from its dual, bidirectional signaling capacity, with the afferent arm dominating the information flow.

2.1. Afferent Pathway: Sensory Diversity and Gut Surveillance

The vast majority (>80%) of vagal fibers are afferent, originating in the Nodose Ganglia and terminating centrally in the NTS (Nucleus Tractus Solitarius). These fibers exhibit structural and functional heterogeneity.

- **Fiber Subtypes:** Afferent fibers include **myelinated A/B fibers** dedicated primarily to mechanosensation (e.g., gastric distension, fullness), and crucial **unmyelinated C fibers** that function as polymodal receptors, responding to chemical, hormonal, and inflammatory stimuli (Bonaz et al., 2017). These C-fibers are the primary mediators of nociception and immune surveillance.
- **Microbial and Hormonal Interplay:** Vagal afferent neurons indirectly monitor the metabolic status of the gut microbiota. **Short-Chain Fatty Acids (SCFAs)** (butyrate, propionate, acetate) the key metabolic products of bacterial fermentation—activate specialized G-protein coupled receptors (GPCRs) like GPR41 and GPR43 expressed on enteroendocrine L-cells and other cells (De Vadder et al., 2014). This activation triggers the release of gut peptides (such as CCK, GLP-1, and Peptide YY), which then directly stimulate the vagal afferents, transmitting information about microbial activity and satiety to the brain (Goswami et al., 2018; Tsilimigras et al., 2023).

Vol.9, No.06; 2025

ISSN: 2581-3366

- **Cytokine Transduction and Central Alert:** Vagal afferent terminals are highly sensitive to systemic inflammation. They express specific receptors for key pro-inflammatory cytokines, including Interleukin-1 beta (IL-1 beta) and Tumor Necrosis Factor alpha (TNF-alpha), acting as a crucial interface between the immune and nervous systems (Ghoshal & Srivastava, 2020). Detection of these molecules and PAMPs (Pathogen-Associated Molecular Patterns) at peripheral sites rapidly signals the brainstem (NTS) about the presence of inflammation, initiating the central components of the "inflammatory reflex." This signal is then relayed to central autonomic networks (including the Paraventricular Nucleus and Amygdala), integrating inflammation into stress and descending pain modulatory circuits (Morris et al., 2020).

2.2. Efferent Pathway: Initiation of the Cholinergic Anti-Inflammatory Reflex

The efferent fibers, originating mainly from the Dorsal Motor Nucleus (DMN) and Nucleus Ambiguus, constitute the motor and secretomotor output. This pathway mediates the rapid neural feedback required to control the innate immune response, forming the crucial efferent arm of the **Inflammatory Reflex** (Tracey, 2007).



Figure 1. Bidirectional gut–brain communication mediated by the vagus nerve.

Vol.9, No.06; 2025

ISSN: 2581-3366

The diagram illustrates the dual-directional signaling between the gastrointestinal tract and the central nervous system via the vagus nerve. Approximately 80% of vagal fibers are afferent, transmitting microbial, mechanical, and immune-derived signals from the gut to the brain. Efferent vagal pathways modulate gastrointestinal motility, autonomic regulation, and immune responses, contributing to the control of systemic inflammation through neural, endocrine, and cytokine-mediated mechanisms. Circulating immune and endocrine signals further integrate gut-derived information into the broader gut–brain axis.

3. Mechanism of Action: The Cholinergic Anti-Inflammatory Pathway (CAP)

The CAP is the neurophysiological mechanism by which the efferent Vagus Nerve acutely and potently suppresses peripheral and systemic inflammation, acting as the body's intrinsic anti-inflammatory "brake" (Tracey, 2007).

- **The Reflex Arc and Target Organs:** The vagal signal travels down the efferent pathway. While some direct modulation occurs, the primary systemic effect is mediated via a neuro-neural-immune synapse, particularly in the **spleen** (the largest secondary lymphoid organ). The vagal signal travels to the celiac ganglion, stimulating the splenic nerve (sympathetic), which then releases norepinephrine (NE) within the spleen. The NE then stimulates splenic CD4+ T cells to release **Acetylcholine** (ACh), which is the key molecule for the CAP [26].
- **The Alpha 7 Nicotinic Acetylcholine Receptor:** ACh acts upon the **alpha 7 nicotinic Acetylcholine Receptor** (α7nAChR). This receptor is a highly expressed homopentameric ligand-gated ion channel on cytokine-producing immune cells, most critically **macrophages**, monocytes, and certain T-cells, marking it as the essential molecular mediator of the CAP (Wang et al., 2003; Zhang et al., 2021).

- **Inhibition of Cytokine Release: Intracellular Cascades:** The binding of ACh to the α7nAChR triggers a rapid increase in intracellular calcium, initiating a cascade that leads to:
  - **JAK2/STAT3 Pathway Activation:** Phosphorylation and activation of Janus Kinase 2 (JAK2) and Signal Transducer and Activator of Transcription 3 (STAT3) occurs, which suppresses the gene transcription of pro-inflammatory factors (Li et al., 2017).

  - **NF-kappa-beta Blockade:** The core anti-inflammatory effect is the inhibition of the nuclear translocation of the transcription factor NF-kappa-beta (NF-kB), the master regulator of inflammatory gene expression (Goren et al., 2007). By blocking NF-kB activity, the release of major pro-inflammatory mediators, including **Tumor Necrosis Factor alpha (TNF-alpha)**, **Interleukin-1 beta (IL-1 beta)**, and **Interleukin-6 (IL-6)**, is potently suppressed (Wang et al., 2003).

Vol.9, No.06; 2025

ISSN: 2581-3366

- **Other Protective Roles:** CAP activation is linked to promoting **autophagy** (cellular cleanup) in microglia, aiding in the resolution of neuroinflammation (Li et al., 2017). Furthermore, stable vagal tone strengthens the intestinal epithelial barrier by regulating the expression and localization of tight junction proteins, thereby preventing antigen translocation (Guarino et al., 2017).



Figure 2. Neural regulation of inflammation via the vagus nerve ACh/α7nAChR pathway.

Vol.9, No.06; 2025

ISSN: 2581-3366

This diagram illustrates the Cholinergic Anti-Inflammatory Pathway (CAP), in which efferent vagal fibers activate the celiac ganglion and subsequently the splenic nerve. Norepinephrine released from splenic nerve terminals stimulates acetylcholine-producing immune cells, enabling ACh to bind to α7 nicotinic acetylcholine receptors (α7nAChR) on macrophages. Activation of α7nAChR suppresses the production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-18) and inhibits neutrophil recruitment and diapedesis. Afferent vagal fibers simultaneously relay peripheral inflammatory signals—including PAMPs and cytokines—to the central nervous system. Through this bidirectional loop, the CAP modulates systemic immune responses, limits excessive inflammation, and maintains gut–immune–neural homeostasis.

4. Clinical Relevance and Pathophysiological Links

Dysfunction of the Vagus Nerve, often quantified by a reduction in **Heart Rate Variability (HRV)**—a physiological measure of vagal tone—is a pervasive feature across numerous inflammatory, chronic, and stress-related diseases (Mairesse et al., 2021). Low HRV is consistently associated with worse outcomes and higher inflammatory markers.

- **Inflammatory Bowel Diseases (IBD) and Visceral Pain:** IBD patients consistently exhibit significantly impaired vagal function and low HRV (Pellissier et al., 2014). This failure to adequately activate the CAP is a core mechanism contributing to the persistence of chronic intestinal inflammation, visceral hypersensitivity, and high comorbidity rates with fatigue and depression (Meregnani et al., 2011).
- **Autoimmune Diseases (e.g., Rheumatoid Arthritis):** The systemic anti-inflammatory power of the CAP is validated by its effectiveness in models of Rheumatoid Arthritis (RA). VNS has been shown to reduce joint inflammation and severity in RA patients, confirming its potential to modulate systemic, non-gut-specific immune responses through the splenic reflex [27, 28].
- **Neuropsychiatric and Neurodegenerative Disorders:** The bidirectional inflammatory signaling via the Vagus Nerve is implicated in central disorders. Neuroinflammation signaled through the vagal afferents is a major mechanism linking peripheral immune activation to depression, fatigue, and anxiety (Hoge et al., 2020). Conversely, the hypothesis that alpha-synuclein pathology in **Parkinson's Disease** may originate in the ENS and spread retrogradely to the brainstem via the Vagus Nerve suggests a direct vagal involvement in neurodegeneration (Phillips & Redgrave, 2020).
- **Metabolic and Cardiovascular Syndrome:** Vagal tone plays a crucial role in regulating energy homeostasis, gastric emptying, and insulin sensitivity. Dysfunction may contribute to the low-grade systemic inflammation characteristic of obesity, **Type 2 Diabetes**, and cardiovascular disease, highlighting the Vagus Nerve as a key neuro-metabolic and neuro-cardiac regulator (Guzik et al., 2023).

Vol.9, No.06; 2025

ISSN: 2581-3366



Figure 3. Invasive and non-invasive vagus nerve stimulation (VNS) modalities.

The illustration compares invasive VNS—delivered through an implanted cervical electrode—with two non-invasive techniques: transcutaneous cervical VNS (tcVNS) and transcutaneous auricular VNS (taVNS). tcVNS administers stimulation over the cervical vagus nerve using a surface device, whereas taVNS targets the auricular branch of the vagus nerve, primarily through the cymba conchae and external ear canal. These approaches modulate afferent vagal activity without the need for surgical implantation, offering accessible alternatives for neuromodulation in clinical and experimental settings.

5. Therapeutic Strategies Targeting the Vagus Nerve

The profound anti-inflammatory potential of the Vagus Nerve has propelled research into "Bioelectronic Medicine" and sophisticated behavioral interventions designed to enhance vagal output.

5.1. Vagus Nerve Stimulation (VNS)

VNS offers a precise, electrically mediated method to directly activate the CAP, providing rapid anti-inflammatory effects that complement traditional pharmacology.

- **Invasive Cervical VNS (iVNS):** Already FDA-approved for refractory epilepsy and treatment-resistant depression, iVNS is a major focus for its systemic anti-inflammatory potential. Clinical trials in severe Crohn's Disease have demonstrated that chronic iVNS can significantly reduce inflammatory markers (like CRP) and promote mucosal healing, positioning it as a potentially drug-sparing or adjunct therapy (Sinniger et al., 2017; Redgrave et al., 2018).
- **Non-Invasive VNS (n-VNS):** Due to the high cost and invasiveness of iVNS, non-invasive methods, particularly **Transcutaneous Auricular VNS (tVNS)** (stimulating the ABVN at the ear), have gained prominence. tVNS offers a patient-friendly method to acutely elevate vagal tone, demonstrating efficacy in reducing circulating pro-inflammatory

Vol.9, No.06; 2025

ISSN: 2581-3366

cytokines, managing symptoms in IBS, and treating chronic pain conditions like fibromyalgia (La Marca et al., 2022).

- **Future Directions and Specificity:** Future VNS research focuses on developing targeted protocols. Studies on the molecular level suggest that VNS regulates immune cell trafficking and function by modulating pathways like **SUMOylation**, indicating highly specific molecular targets (Johnson et al., 2024). Furthermore, selective targeting of specific vagal branches (e.g., the abdominal branch) may allow for organ-specific anti-inflammatory action with fewer side effects.

5.2. Interventional Techniques: Vagal Nerve Hydrodissection

Beyond electrical stimulation, direct interventional techniques are emerging. **Ultrasound-guided vagal nerve hydrodissection** represents a novel physical technique aimed at freeing the nerve from surrounding fibrotic tissue or mechanical compression, particularly relevant for patients with chronic pain and autonomic dysfunction (Lam et al., 2024). This technique involves injecting a solution (such as %5 Dextrose without local anesthetic) around the Vagus Nerve, suggesting the therapeutic benefit is derived not from nerve block, but from **mechanical decompression** and promotion of nerve gliding and healing, potentially enhancing its afferent and efferent signaling capacity in chronic conditions (Lam et al., 2024).

5.3. Lifestyle and Microbiota Interventions

- **Behavioral Vagal Toning:** Non-pharmacological strategies that enhance autonomic regulation are crucial. Practices that deliberately increase **HRV**, such as slow-paced, diaphragmatic breathing (at approximately 6 breaths/minute), mindfulness, and certain types of yoga, are proven methods to enhance the body's intrinsic anti-inflammatory capacity and improve emotional regulation (Mairesse et al., 2021).
- **Microbiota Modulation:** Specific dietary components and therapeutic interventions (e.g., specific **probiotics** or **prebiotics**) that promote the growth of SCFA-producing bacteria act as indirect "vagal boosters" (De Vadder et al., 2014; Browning, 2024). Modulating the gut environment to increase vagal afferent activation is a key area for combination therapies.

6. Conclusion and Future Perspectives

The Vagus Nerve is unequivocally the **central neural mediator** of the anti-inflammatory crosstalk between the brain and the body's immune system. Its sophisticated dual role—as a meticulous sensor of inflammatory and microbial status and a rapid, potent suppressor of the innate immune response via the CAP—makes it a critical and highly attractive target in chronic disease management. Research has rapidly moved towards actively leveraging VNS for therapeutic effect. Future efforts must prioritize: 1) Developing personalized and closed-loop **VNS protocols** based on real-time HRV and inflammatory biomarker feedback; 2) Exploring synergistic effects of combining **n-VNS with microbiota-targeted interventions**; 3) Further elucidating the precise molecular modulations (e.g., STAT3 activity, autophagy) to maximize

clinical efficacy; and 4) Investigating the role of afferent vagal stimulation in modulating central reward and mood pathways. The Vagus Nerve represents one of the most exciting and promising frontiers in translational neuroimmunology and bioelectronic medicine.

7. References

Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. *Nature Reviews Neuroscience*, 13(10), 701–712.

Bonaz, B., Picq, D., Tarnaud, S., et al. (2018). Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders. *Frontiers in Psychiatry*, 9:44.

Pellissier, S., Dantzer, C., Mondillon, V., et al. (2014). Relationship between vagal tone, cortisol, TNF-α, IL-6 and IL-1β in inflammatory bowel diseases. *PLoS One*, 9(9), e105328.

Porges, S. W. (2007). The polyvagal perspective. *Biological Psychology*, 74(2), 116–143.

Tracey, K. J. (2007). The inflammatory reflex. *Nature*, 420(6917), 853-859.

Bonaz, B., Sinniger, V., & Pellissier, S. (2017). Vagal tone: effects on sensitivity, motility, and inflammation. *Neurogastroenterology & Motility*, 29(1), 1–13.

De Vadder, F., Kovatcheva-Datchary, P., Nilsson, A., et al. (2014). Microbiota-Produced Butyrate Promotes the Production of Gut Hormones through Direct Vagal Stimulation. *Cell Host & Microbe*, 14(1), 85–94.

Goswami, P., et al. (2018). Short chain fatty acids suppress food intake by activating vagal afferent neurons. *The Journal of Physiology*.

Ghoshal, U. C., & Srivastava, D. (2020). Vagus nerve stimulation in inflammatory bowel disease. *World Journal of Gastroenterology*, 26(18), 2132-2140.

Morris, G., et al. (2020). Neural pathways connecting the vagus nerve to central pain networks. *Brain Structure and Function*.

Wang, H., Yu, M., Ochani, M., et al. (2003). α7 nicotinic acetylcholine receptor is an essential upstream regulator of TNF-α release in macrophages. *The Journal of Experimental Medicine*, 198(12), 1793-1799.

Zhang, Y., et al. (2021). Neuroinflammation Modulation via α7 Nicotinic Acetylcholine Receptor and Its Chaperone, RIC-3. *Mediators of Inflammation*.

Li, W., et al. (2017). Autophagy Plays an Important Role in Anti-inflammatory Mechanisms Stimulated by Alpha7 Nicotinic Acetylcholine Receptor. *Frontiers in Immunology*.

Goren, I., et al. (2007). Essential role of the α7 nicotinic acetylcholine receptor in the prevention of NF-κβ activation and TNF release by inflammatory macrophages. *The Journal of Immunology*, 179(12), 8548-8555.

Guarino, M., et al. (2017). Vagus nerve stimulation: a new promising strategy for the treatment of Crohn's disease. *Clinical and Experimental Gastroenterology*, 10, 107-115.

Mairesse, O., et al. (2021). The effects of deep and slow breathing on the brain: a systematic review. *Neuroscience and Biobehavioral Reviews*, 124, 1-17.

Meregnani, J., Martinez, V., Gaultier, E., et al. (2011). Vagus nerve stimulation reduces intestinal inflammation and improves outcome in a mouse model of Crohn's disease. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 301(3), G607-G614.

Goudman, L., et al. (2024). The brain-gut axis and chronic pain: mechanisms and therapeutic opportunities. *Frontiers in Neuroscience*.

Phillips, C. B., & Redgrave, J. (2020). The Vagus Nerve and Parkinson's Disease: From Animal Models to Clinical Trials. *Frontiers in Neurology*, 11, 781.

Hoge, E. A., et al. (2020). The vagus nerve and anxiety disorders: a systematic review. *Biological Psychiatry*, 88(8), 643-652.

Sinniger, V., et al. (2017). A pilot study of vagus nerve stimulation in Crohn's disease. *Clinical Trials NCT01569503*.

Redgrave, J., et al. (2018). The effects of transcutaneous vagus nerve stimulation on the functional brain: an fMRI study. *Brain Stimulation*, 11(2), 332-340.

La Marca, A., et al. (2022). Transcutaneous Vagus Nerve Stimulation (tVNS) as a therapeutic tool for chronic pain and inflammation. *Journal of Pain Research*, 15, 787-802.

Johnson, B., et al. (2024). How Nerve Stimulation Could Ease Inflammatory Bowel Disease (SUMOylation mechanism). *Science Translational Medicine*.

Browning, K. N. (2024). The Vagus Nerve and Sleep/Circadian Rhythms: Focus on the Microbiota. *Physiological Reviews*.

Lam KHS, Su DC, Wu YT, Varrassi G, Suryadi T, Reeves KD. (2024). A Novel Ultrasound-Guided Bilateral Vagal Nerve Hydrodissection With 5\% Dextrose Without Local Anesthetic for Recalcitrant Chronic Multisite Pain and Autonomic Dysfunction. Cureus, 16(7): e63609.

Rosas-Ballina, M., et al. (2008). Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve-to-spleen inflammatory reflex. *Science*, 320(5875), 671-674.

Koopman, F. A., et al. (2016). Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. *PNAS*, 113(33), 8234-8239.

Guzik, A., et al. (2023). Vagal Tone and Heart Rate Variability in Cardiovascular and Metabolic Diseases. *Frontiers in Physiology*, 14, 1157833.

Chang, H. D., et al. (2021). Vagus nerve stimulation and its effects on the metabolic syndrome. *Journal of Neuroinflammation*, 18(1), 114.

Kringelbach, M. L., et al. (2020). The GBA and reward: relevance to mood and mental health. *Nature Reviews Neuroscience*, 21(11), 661-672.

Tsilimigras, D. I., et al. (2023). The Vagus Nerve and Microbiota-Gut-Brain Axis in Health and Disease: Current Understanding and Future Directions. *Cureus*, 15(4), e37719.